E3 PreliminaryPreliminaryPEM unclearPeer-reviewedMachine draft
The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.
See, D M, Cimoch, P, Chou, S et al. · Integrative physiological and behavioral science : the official journal of the Pavlovian Society · 1998 · DOI
Quick Summary
This study tested whether a supplement containing eight specific sugars (called glyconutrients) could help fix immune system problems in ME/CFS patients. Researchers added the supplement to immune cells from ME/CFS patients and healthy controls in a laboratory dish and measured whether it improved immune function. The supplement appeared to increase the activity of several types of immune cells and reduce cell death in ME/CFS patients' immune cells.
Why It Matters
This study contributes to understanding whether glyconutrient supplementation could address documented immune abnormalities in ME/CFS, including reduced NK cell function and altered immune cell surface markers. If validated in clinical trials, this approach could offer a relatively accessible intervention targeting immune dysregulation in ME/CFS.
Observed Findings
- CD5, CD8, and CD11a cell surface expression were significantly lower in CFS PBMC compared to healthy controls.
- Glyconutrient addition significantly increased glycoprotein expression (CD5, CD8, CD11a) on CFS PBMC when stimulated with phytohemagglutinin.
- NK cell activity was reduced in CFS patients and was significantly enhanced by glyconutrient treatment in a 51Cr release assay (p<0.01).
- Apoptosis (programmed cell death) rates were significantly elevated in CFS patient PBMC and were significantly reduced by 48-hour glyconutrient incubation.
Inferred Conclusions
- Glyconutrients can partially normalize abnormal immune cell surface markers in ME/CFS PBMC in vitro.
- Glyconutrient supplementation enhances NK cell cytotoxic function against virally infected cells in ME/CFS patients.
- Glyconutrients reduce excessive cell death in ME/CFS immune cells, potentially addressing a feature of immune dysregulation.
Remaining Questions
- Does oral glyconutrient supplementation achieve sufficient bioavailability to produce the same immune effects observed in vitro?
- Do these in vitro immune improvements correlate with symptom reduction or functional recovery in ME/CFS patients?
- What is the optimal dosing, duration, and formulation of glyconutrient supplementation for clinical efficacy?
What This Study Does Not Prove
This laboratory study does not prove that glyconutrients improve ME/CFS symptoms in actual patients—only that they affect immune cells in a test tube. It does not establish whether oral supplementation delivers these compounds to cells effectively, whether the improvement persists long-term, or whether immune changes would translate to clinical benefit. Correlation between in vitro immune changes and patient outcomes cannot be inferred from this mechanistic work.
Tags
Symptom:Fatigue
Biomarker:CytokinesBlood Biomarker
Method Flag:Weak Case DefinitionSmall SampleExploratory Only
Metadata
- DOI
- 10.1007/BF02688668
- PMID
- 9829439
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →